Cannabis and Cancer: Science, Symptoms, and Survival: See the Youtube Documentary
Editor's Note: Cannabis laws and regulations vary by country, state, and territory. This interview is for educational purposes only. Cannabis products discussed here are not endorsed by MedicalResearch.com. Patients should consult their oncologist or healthcare provider before using any cannabis or cannabinoid product, particularly during cancer treatment. Cannabis products should not be used while driving, by children, if pregnant, nursing or planning to become pregnant or mixed with other substances that can affect cognition. Cannabis products may also be contraindicated in other medical conditions or situations.
MedicalResearch.com: What is the background for this documentary? What are the primary components of cannabis plants? Response: I created Cannabis and Cancer because cannabis is now widely discussed by patients, clinicians, policymakers, and the general public, but there is still a lot of confusion about what the science actually says. Much of the public conversation treats cannabis as either broadly harmful or broadly beneficial. The reality is more complex. The documentary is meant to separate questions that are often conflated: whether cannabis exposure may influence the risk of developing cancer, whether cannabis use may affect cancer treatment or symptoms, and whether it may influence survival after a cancer diagnosis. These are very different scientific questions, and each one requires a different type of evidence. Cannabis plants contain many biologically active compounds. The most widely discussed are cannabinoids, especially THC and CBD. THC is the main intoxicating compound and is responsible for many of the psychoactive effects. CBD is not intoxicating in the same way, but it still has biological effects. Cannabis also contains other cannabinoids, terpenes, flavonoids, and plant compounds that may influence how different products affect the body.
Source: IMAGE[/caption]
Dr. Kruger[/caption]
MedicalResearch.com: What is the background for this study?
[caption id="attachment_72137" align="alignleft" width="100"]
Dr. Felicione[/caption]
Response: Alcohol consumption, especially heavy alcohol consumption, is associated with many health risks and nearly 200 different health conditions and diseases. Reducing alcohol consumption reduces the risks and harms from alcohol. Previous research has demonstrated that people have reduced their alcohol consumption when they have access to cannabis. Cannabis beverages have emerged in States where cannabis is legal for adult or medical use.
Dr. Dunbar[/caption]
MedicalResearch.com Interview with:
Michael S. Dunbar, PhD

Elena Stains[/caption]
Elena Stains
Medical Student
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: In 2019 to 2020, 2.5% of Americans reported using cannabis for medical needs, compared to 1.2% in 2013-2014, representing a 12.9% annual increase1. Forty states and the District of Columbia have legislation for some form of medical cannabis (MC) in 2024. Because MC is not federally legalized, each state creates its own legislation on the conditions that qualify a person for MC, without any standardized process to determine what qualifying conditions (QC) are proven to be aided by MC. Thus, the QCs chosen by states vary widely. Common QCs include cancer, dementia, and PTSD.
The National Academies of Sciences, Engineering, and Medicine (NAS) published a report in 2017 on the evidence for the therapeutic effects of cannabis and cannabinoids for over twenty conditions2. This report reviews the evidence of effectiveness of medical cannabis for the most common QCs chosen by states. The researchers at Geisinger Commonwealth School of Medicine aimed to compare the evidence found by the NAS report with the QCs of 38 states (including the District of Columbia) in both 2017 and 2024. QCs were categorized based on NAS-established level of evidence: limited, moderate, or substantial/conclusive evidence of effectiveness, limited evidence of ineffectiveness, or no/insufficient evidence to support or refute effectiveness (Table 1).